Nightstar Therapeutics Company
Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies.
Technology:
Neurological Disorders
Industry:
Gene Therapy
Headquarters:
London, England, United Kingdom
Founded Date:
2013
Employees Number:
11-50
Funding Status:
M&A
Investors Number:
4
Total Funding:
$174.6M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership